Emyria Ltd's (ASX:EMD) Michael Winlo speaks to Proactive's Andrew Scott following the news it's been awarded Therapeutic Goods Administration (TGA) approval for its unique smartphone-based cardiovascular monitoring software. Winlo says the medical-grade monitoring tool, which runs on both Apple and Android phones, opens up further opportunities for them to remotely capture objective health data for its drug development, telemedicine and consumer healthcare projects.
Emyria welcomes TGA approval for its smartphone-based cardiovascular monitoring software
